INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INOVIO (NASDAQ: INO) reported Q2 2026 results and said the FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is progressing toward a PDUFA target date of Oct. 30, 2026. Cash and investments were $36.7M at June 30, 2026. Net loss was $6.0M. ApolloBio reported positive Phase 3 topline results for VGX-3100 in China.
How this was made
The 30-second read
Why it matters
The key tradable elements are the FDA review progress toward a defined PDUFA date, commercialization readiness steps, and updated cash runway into late Q1 2027.
Market read
Regulatory process milestones and a defined PDUFA date are the primary catalyst, while financials and cash runway inform financing risk and timing of commercialization expectations.
What to watch
The cash balance fell to $36.7 million at June 30, 2026 (excluding July proceeds), and the net loss includes a non-cash warrant fair value gain that can reverse with share-price moves.
Background
INOVIO is developing DNA medicines for HPV-related diseases and other indications, with INO-3107 under FDA accelerated approval review for RRP.
Ticker impact
INOVIO says FDA BLA review for INO-3107 is advancing toward a PDUFA target date of Oct. 30, 2026, with late-cycle review and inspections completed.
Bias to upside into the Oct. 30, 2026 PDUFA window, with volatility around any FDA feedback on confirmatory trial design.
The article provides concrete FDA process milestones (late-cycle meeting, pre-licensure inspections) and a specific PDUFA date, alongside funding into late Q1 2027 and launch readiness steps.
Market effects
Supports sentiment for DNA medicine and HPV-related therapeutics, but impact is company-specific given the single-issuer regulatory update.
Limited direct regional spillover; VGX-3100 China partner data may influence China HPV immunotherapy sentiment.
Moderate global relevance via cross-border development (US FDA review and China partner Phase 3 topline), but no new global policy or competitive event is disclosed.
Counterpoint
FDA did not discuss preliminary accelerated-approval eligibility comments, and confirmatory trial design feedback is still pending, leaving approval probability uncertain.
Key entities
- programINO-3107
INOVIO’s investigational DNA medicine for recurrent respiratory papillomatosis (RRP) under FDA BLA review.
- regulatorFDA
Agency reviewing INO-3107 BLA under accelerated approval program with an Oct. 30, 2026 PDUFA target date.
- programVGX-3100
INOVIO’s investigational DNA immunotherapy for cervical dysplasia, with positive Phase 3 topline results reported by ApolloBio.
- partnerApolloBio
Greater China partner that reported positive Phase 3 topline results for VGX-3100.
- service_providerSyneos Health
Engaged to recruit and deploy Medical Science Liaisons and serve as contract sales organization for INO-3107 commercialization.
